Kazi, Dhruv S, Joanne Penko, Pamela G Coxson, Andrew E Moran, Daniel A Ollendorf, Jeffrey A Tice, and Kirsten Bibbins-Domingo. 2017. “Updated Cost-Effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.”. JAMA 318 (8): 748-50.
Abstract
This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.